<DOC>
	<DOCNO>NCT01560793</DOCNO>
	<brief_summary>This study evaluate safety immunogenicity VAX161B [ STF2.HA5 H5N1 ] , recombinant , inactivate , subunit influenza vaccine give two dose regimen range dos .</brief_summary>
	<brief_title>Safety Immunogenicity Novel H5N1 Influenza Vaccine Healthy Adults Age 18-49 Years</brief_title>
	<detailed_description>The purpose study test investigational vaccine know `` VAX161B '' . VAX161B vaccine influenza A virus subtype H5N1 avian influenza virus ( bird flu ) . In study , subject receive VAX161B vaccine one five dos see might best . VaxInnate want find safe vaccine well tolerated people receive . To measure effective type vaccine , VaxInnate test ability body develop immune response , mean well body recognize defend influenza virus .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>male female age 18 49 year inclusive give write informed consent participate healthy , determined medical history , physical examination comprehension study requirement willing provide multiple blood specimen collect venipuncture . Subjects psychiatric illness , chronic illness would interfere participation interpretation result clinically significant abnormal liver function test positive serology HBsAg HCV antibody impair immune response history anaphylactic type reaction inject vaccine history drug chemical abuse year prior screen history GuillainBarr√© Syndrome history chronic obstructive pulmonary disease history lung disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Vaccines</keyword>
	<keyword>H5N1</keyword>
</DOC>